HOMEVULNERABILITIESCVE-2022-47376
HIGH

CVE-2022-47376

CWE-257Published: June 13, 2023· Updated: Jun 17, 2026

7.3
CVSS v3.1

Official Description

The Alaris Infusion Central software, versions 1.1 to 1.3.2, may contain a recoverable password after the installation. No patient health data is stored in the database, although some site installations may choose to store personal data.

NVD Source

Technical Analysis

CVE-2022-47376 requires local access, meaning attackers must already have a foothold on the target system.

Exploitation requires low privileges, which limits the exposure to scenarios where an attacker has already gained initial access.

A successful exploit results in complete confidentiality breach (data exposure), full integrity compromise (data manipulation), with a CVSS base score of 7.3.

CVSS v3.1 Vector Breakdown

Exploitability
Attack VectorLocal
Attack ComplexityLow
Privileges Req.Low
User InteractionNone
ScopeUnchanged
Impact
ConfidentialityHigh
IntegrityHigh
AvailabilityLow
CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:L

Affected Vendors & Products

bd1 product(s)
alaris infusion central
Source: NVD CPE · 1 total CPE entries

Exploit & PoC Resources

NO KNOWN EXPLOITNo public exploit confirmed at this time
External links open in a new tab. Always verify in a controlled environment before use.

Official Patches & Advisories

All References (2)

Quick Facts

CVE IDCVE-2022-47376
CVSS Score7.3 / 10
SeverityHIGH
WeaknessCWE-257
CISA KEVNo
Affected1 vendor(s)
PublishedJun 13, 2023

Related CVEs (CWE-257)

Recommended Actions

  • Apply vendor patches immediately
  • Monitor CVE-2022-47376 in threat intel feeds
  • Review IDS/IPS signatures for exploitation attempts
Data sourced from NVD (NIST), CISA KEV, and EPSS (FIRST). Analysis generated by CTIWATCH.COM. CVE data is provided under the NVD usage policy.